Yara Tedavisinde Kök Hücre ve Trombositten Zengin Plazmanın Etkileri
Özet
Yara iyileşmesi; inflamasyon, proliferasyon ve remodelling basamaklarından oluşan, akut yaraların 4-6 haftada kapandığı kompleks bir süreçtir; ancak faktör eksiklikleri veya enfeksiyon bu süreci uzatarak kronik yaralara yol açar. Kronik yara tedavisinde hücresel tedaviler öne çıkmakta olup, kök hücreler kendini yenileme ve farklılaşma yetenekleriyle kritik bir rol oynar. Blastokistten elde edilen embriyonik kök hücreler sınırsız çoğalma potansiyeline sahipken, tümörleşme riski ve etik tartışmalar taşır. Laboratuvarda geliştirilen uyarılmış pluripotent kök hücreler (uPKH) ise immün reddi ve etik kaygıları ortadan kaldırmıştır. Erişkin kök hücrelerinden mezenkimal kök hücreler (MKH) kemik iliği ve yağ dokusundan elde edilir. Kemik iliği kaynaklı hücreler altın standart kabul edilse de az miktarda bulunurlar ve kültür edilmeleri gerekir. Yağ kaynaklı kök hücreler (ASC) ise vücutta bolca bulunur, kolay elde edilir ve kültür edilmeden stromal vasküler fraksiyon (SVF) olarak direkt ameliyathanede ayrıştırılıp kullanılabilir. Kök hücreler ortamdaki sinyallere göre neovaskülarizasyonu artırarak veya sitokinler salgılayarak yara iyileşmesini parakrin (indirekt) yolla destekler; ancak fibrosis veya keloid varlığında skar dokusunu artırabilirler. Diğer bir otolog tedavi olan Trombositten Zengin Plazma (TZP), santrifüj yöntemiyle kandan elde edilen ve normal yara iyileşmesini taklit eden, alfa granüllerinde 7 temel büyüme faktörü barındıran bir solüsyondur. Kısa yarı ömrü nedeniyle tekrarlayan enjeksiyonlar gerektiren TZP, kronik yaralarda destekleyici bir tedavi seçeneğidir. Sonuç olarak, medikolegal engeller ve GMP standartları aşıldığı takdirde MKH ve kolay hazırlanan TZP uygulamaları kronik yara tedavisinde standart tedaviler arasında yer alacaktır.
Wound healing is a complex process consisting of inflammation, proliferation, and remodeling phases, where acute wounds close in 4-6 weeks; however, factor deficiencies or infection prolong this process, leading to chronic wounds. Cellular therapies stand out in chronic wound treatment, and stem cells play a critical role with their self-renewal and differentiation abilities. Embryonic stem cells derived from blastocysts have unlimited proliferation potential but carry tumor risk and ethical debates. Induced pluripotent stem cells (iPSCs) developed in the laboratory have eliminated immune rejection and ethical concerns. Among adult stem cells, mesenchymal stem cells (MSCs) are obtained from bone marrow and adipose tissue. Bone marrow-derived cells are considered the gold standard, but they are found in small amounts and require culturing. Adipose-derived stem cells (ASCs) are abundant in the body, easily obtained, and can be isolated and used directly in the operating room as stromal vascular fraction (SVF) without culturing. Stem cells support wound healing through paracrine (indirect) pathways by increasing neovascularization or secreting cytokines according to environment signals; however, they can increase scar tissue in the presence of fibrosis or keloid. Platelet-Rich Plasma (PRP), another autologous treatment, is a solution obtained from blood via centrifugation that mimics normal wound healing and contains 7 essential growth factors in its alpha granules. Requiring repeated injections due to its short half-life, PRP is a supportive treatment option for chronic wounds. Consequently, if medicolegal obstacles and GMP standards are overcome, MSC and easily prepared PRP applications will take their place among standard treatments in chronic wound care.
Referanslar
Broughton G 2nd, Janis JE, Attinger CE. The basic science of wound healing. Plast Reconstr Surg. 2006;117(7 Suppl):12S-34S.
Lazarus GS, Cooper DM, Knighton DR, et. al.: Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994; 130:489-493.
Can A. A Concise Review on the Classification and Nomenclature of Stem Cells. Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology. 2008;25:57–59.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998 ;282(5391):1145-1147.
Brivanlou AH, Gage FH, Jaenisch R, et al. Stem Cells: Enhanced: Setting Standards for Human Embryonic Stem Cells. Science. 2003;300:913–916.
Wilmut I, Schnieke AE, McWhir J, et al. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385:810–813.
Jiao J, Chen DF. Induction of Neurogenesis in Nonconventional Neurogenic Regions of the Adult Central Nervous System by Niche Astrocyte-Produced Signals. Stem Cells. 2008;26:1221–1230.
Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 2006;126:663–676.
Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016;17(3):183-193.
Yoshida Y, Yamanaka S. Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Circ Res. 2017;120(12):1958-1968
da Silva Meirelles L, Caplan AI, Nardi NB. In Search of the In Vivo Identity of Mesenchymal Stem Cells. Stem Cells. 2008a;26:2287–2299.
Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452–454.
Can A. Kök hücrelerin genel özellikleri, embriyonik ve yetişkin kök hücrelere genel bakış. Hematolog 2014;4:238-254.
Phinney DG, Prockop DJ. Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair-Current Views. Stem Cells. 2007;25:2896–2902.
Taupin P. Therapeutic potential of adult neural stem cells. Recent Patents on CNS Drug Discovery. 2006;1:299–303.
Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005–11
Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther. 2010;21(9):1045-1056
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211-28.
Aust L, Devlin B, Foster SJ, Halvorsen YD, Hicok K, du Laney T, Sen A, Willingmyre GD, Gimble JM. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy. 2004;6(1):7-14
Oberbauer E, Steffenhagen C, Wurzer C, Gabriel C, Redl H, Wolbank S. Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art. Cell Regen. 2015;30;4:7
Chu DT, Phuong TNT, Tien NLB, Tran DK, Thanh VV, Quang TL, Truong DT, Pham VH, Ngoc VTN, Chu-Dinh T, Kushekhar K. An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells. Int J Mol Sci. 2020;21(3):708.
Ferrin I, Beloqui I, Zabaleta L, Salcedo JM, Trigueros C, Martin AG. Isolation, Culture, and Expansion of Mesenchymal Stem Cells. Methods Mol Biol. 2017;1590:177-190
Nguyen A, Guo J, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD. Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature. J Plast Reconstr Aesthet Surg. 2016;69(2):170-179.
Guo J, Nguyen A, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD. Stromal vascular fraction: A regenerative reality? Part 2: Mechanisms of regenerative action. J Plast Reconstr Aesthet Surg. 2016;69(2):180-188.
Baer PC, Brzoska M, Geiger H. Epithelial differentiation of human adipose-derived stem cells. Methods Mol Biol. 2011;702:289-298.
Uysal CA, Tobita M, Hyakusoku H, Mizuno H. The Effect of Bone-Marrow-Derived Stem Cells and Adipose-Derived Stem Cells on Wound Contraction and Epithelization. Adv Wound Care (New Rochelle). 2014 Jun 1;3(6):405-413
Tobita M, Uysal CA, Guo X, Hyakusoku H, Mizuno H. “Periodontal tissue regeneration by combined implantation of adipose tissue-derived stem cells and platelet-rich plasma in a canine model” Cytotherapy(ISI), 1517-26, 2013
Uysal AC, M. Tobita, H. Hyakusoku, H. Mizuno, “Adipose-derived stem cells enhance primary tendon repair: biomechanical and immunohistochemical evaluation”, J Plast Reconstr Aesthet Surg (ISI), 1712-9, 2012
H. Mizuno, M. Tobita, A.C. Uysal, “Concise review: Adipose-derived stem cells as a novel tool for future regenerative medicine”, Stem Cells (ISI), 804-10pp, 2012.
H. Orbay, A.C. Uysal, H. Hyakusoku, H. Mizuno, “Differentiated and undifferentiated adipose-derived stem cells improve function in rats with peripheral nerve gaps”, J Plast Reconstr Aesthet Surg (ISI), 657-64pp, 2012
A.C.Uysal, H.Mizuno, M.Tobita, R.Ogawa ,H.Hyakusoku, "The effect of adipose-derived stem cells on ischemia-reperfusion injury: immunohistochemical and ultrastructural evaluation.", Plast Reconstr Surg. (ISI) , 804-15 pp., 2009
Karakaya E, Akdur A, Ok Atilgan A, Uysal AC, Ozturan Ozer HE, Yildirim S, Haberal M. Effect of Adipose-Derived Stem Cells on Colonic Anastomosis in Rats Immunosuppressed With Everolimus: An Experimental Study. Exp Clin Transplant. 2021 Sep;19(9):970-976.
Sumi M, Sata M, Toya N, Yanaga K, Ohki T, Nagai R. Transplantation of adipose stromal cells, but not mature adipocytes, augments ischemia-induced angiogenesis. Life Sci. 2007;16;80(6):559-565
Lu F, Mizuno H, Uysal CA, Cai X, Ogawa R, Hyakusoku H. Improved viability of random pattern skin flaps through the use of adipose-derived stem cells. Plast Reconstr Surg. 2008;121(1):50-58
https://shgm.saglik.gov.tr/TR,34788/201810-kok-hucre-calismalari-hakkinda-genelge.html
https://shgm.saglik.gov.tr/Eklenti/15612/0/kok-hucre-calismalari-genelgepdf.pdf
https://turkok.saglik.gov.tr/TR,47959/kok-hucre-tedavisi-yapilan-hastaliklar.html
Nejadnik H, Tseng J, Daldrup-Link H. Magnetic resonance imaging of stem cell-macrophage interactions with ferumoxytol and ferumoxytol-derived nanoparticles.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(4):e1552)
Liu L, Tseng L, Ye Q, Wu YL, Bain DJ, Ho C. A New Method for PreparingMesenchymal Stem Cells and Labeling with Ferumoxytol for Cell Tracking by MRI. Sci Rep. 2016;18;6:26271.
Castaneda RT, Khurana A, Khan R, Daldrup-Link HE. Labeling stem cells with ferumoxytol, an FDA-approved iron oxide nanoparticle. J Vis Exp. 2011;57:e3482.
Uysal CA, Ertas NM. Does Platelet-Rich Plasma Therapy Increase Pigmentation? J Craniofac Surg. 2017;28(8):e793
Raja VS, Naudi EM. Platelet-rich fibrin: evolution of second-generation platelet concentrate. Indian Journal of Dental Research. 2008;19:42-46
Dhurat R, Shukesh MS. Principles and methods of preperation of platelet-rich plasma: a review and author’s perspective. J Cutan Aesthet Surg. 2014;7:189-197
Arıkan F, Özçaka Ö, Bıçakçı N. Trombositten zengin plazma ve kemik grefti ile kombinasyonun dar kemik içi defektlerde başarısının karşılaştırılması. Ege Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2007;28:151-161
Knighton DR, Fiegal VD, Doucette M. et al. The use of topically applied platelet growth factors in chronic nonhealing wounds: A review. Wounds 1989; 1:71.
Ganio C, Tenewitz FE, Wilson R, et al. The treatment of chronic nonhealing wounds using autologous platelet-derived growth factors. J. Foot Ankle Surg. 1993; 32:263.
Eyuboglu AA, Arpaci E, Albayati A, Uysal AC, Terzi A, Bozalioglu S, Turnaoglu H, Balcik C, Ozkan B, Ertas NM. The Effects of Adipose Derived Stromal Vascular Fraction and Platelet-Rich Plasma on Bone Healing of a Rat Model With Chronic Kidney Disease. Ann Plast Surg. 2020;85(3):316-323
